Poor
Needs Revision
Patient Risk:
Moderate
Summary
Only generic label-supported statements about LIPITOR’s indications/mechanism are aligned. Multiple claims about resveratrol/red wine increasing atorvastatin levels, dose-specific bioavailability increases, and specific interaction/toxicity effects (bleeding, liver damage risk, muscle symptoms as a direct consequence of red wine/resveratrol) are not supported by the provided FDA label excerpts and substantially reduce alignment.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a prescription medication used to lower cholesterol levels and prevent cardiovascular disease.
Supported by label excerpts in Sections 1 (adjunct to diet; indications) and 1.1/14.1 (risk reductions such as MI/stroke/revascularization/angina).
Lipitor belongs to the statin class of drugs that work by inhibiting the production of cholesterol in the liver.
Supported by mechanism language in Section 12.1 (selective competitive inhibitor of HMG-CoA reductase).
Patients should consult their healthcare provider before making changes to diet or medication regimen when taking Lipitor and consuming red wine.
The provided excerpts do not explicitly state this counseling language; however, it is not directly contradicted by the supplied label sections.
Monitoring for muscle pain and weakness and reporting them immediately is recommended as a precaution when taking Lipitor and consuming red wine.
The provided excerpts include skeletal muscle/myopathy warnings (Section 5.1), but they do not support the specific red wine/resveratrol context.
Unsupported Statements
Resveratrol in red wine can increase levels of atorvastatin in the bloodstream when taken with Lipitor.
No resveratrol/red wine interaction is described in the provided label excerpts (drug interaction section provided is about strong CYP3A4 inhibitors and grapefruit juice).
Regular consumption of red wine can lead to adverse interactions with Lipitor.
No red wine/resveratrol interaction is described in the provided label excerpts.
Increased atorvastatin levels can cause muscle damage, leading to muscle pain and weakness.
Section 5.1 supports myopathy/rhabdomyolysis risk generally and temporarily withholding/discontinuing in serious myopathy, but the provided excerpts do not support the specific causal chain 'increased levels from red wine/resveratrol' and do not provide red wine-specific muscle symptom guidance.
The combination of red wine and Lipitor may increase the risk of liver damage, particularly in individuals with pre-existing liver conditions.
The provided label excerpts discuss liver dysfunction generally and recommend LFTs prior to and at 12 weeks after initiation and after dose elevation (Section 5.2), but do not mention red wine/resveratrol or increased liver damage risk from their combination.
Resveratrol can thin the blood, making it more prone to bleeding when combined with Lipitor.
No resveratrol/resveratrol-induced bleeding interaction is described in the provided label excerpts.
Resveratrol can increase the bioavailability of atorvastatin by up to 30%.
No resveratrol or 'up to 30%' bioavailability information appears in the provided label excerpts.
An occasional glass of red wine is unlikely to cause harm with Lipitor.
No red wine-specific safety/threshold guidance is provided in the supplied label excerpts.
Limiting red wine intake to an occasional glass (1–2 ounces) and avoiding regular or excessive consumption can minimize risks when taking Lipitor.
No red wine-specific dosing/threshold guidance is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
An occasional glass of red wine is unlikely to cause harm with Lipitor.
Label Reference
Not directly contradicted by the provided excerpts; however, it is inconsistent with the absence of any red wine-specific safety statements in the supplied label sections and therefore is treated as unsupported rather than a direct contradiction.
Important Omissions
FDA label provides specific interaction warnings for grapefruit juice and strong CYP3A4 inhibitors (e.g., clarithromycin/protease inhibitors/itraconazole) and dose considerations; the AI claims focused on resveratrol/red wine and did not address these on-label interaction warnings.
Importance:
Moderate
Label-directed liver monitoring details (LFTs prior to and at 12 weeks after initiation and after dose elevation) were not included in the AI response, despite liver-function concerns being raised in the AI claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response introduces multiple unsubstantiated red wine/resveratrol interaction and safety threshold claims. While it does not directly recommend an unsafe drug dosing regimen, it may mislead users about interaction risk and distract from on-label interaction precautions (e.g., grapefruit juice/CYP3A4 inhibitors) and monitoring guidance (e.g., LFTs).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Multiple specific claims about resveratrol/red wine interactions, magnitude of atorvastatin bioavailability increase, and safety thresholds are not supported by the provided FDA label excerpts.
Suggested Improvement
Remove or replace red wine/resveratrol interaction claims with label-supported interaction warnings (CYP3A4 strong inhibitors and grapefruit juice) and align any muscle/liver monitoring statements to the label language (e.g., skeletal muscle warnings in Section 5.1; LFT timing in Section 5.2).